- TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Clinical Trial
TESARO 4010-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
The Study Drug is designed to stop cancer from growing by helping the immune system recognize and fight cancer. This study is divided into 3 parts. The purpose of this research study is to: Evaluate the safety of the Study Drug using different doses and schedules, and to evaluate the ability of the Study Drug to reduce the size of the cancer.
- Female Reproductive System
- Male Reproductive System
- Cancer
- Gynecological- Solid Tumor
- Monoclonal Antibody
- PD-1
Eligibility Criteria
- Must be at least 18 years of age Must have advanced or metastatic solid tumor with disease progression after standard treatment Must have positive FLT3 mutation in bone marrow or whole blood Subject cannot have: HIV, Hepatitic B or C, or autoimmune disease
RESEARCH. INNOVATION. DISCOVERY.